Janus Pharmaceuticals, Inc. Announces Successful Phase II Study In Shingles

LOS ANGELES--(BUSINESS WIRE)--Janus Pharmaceuticals Inc. (Janus), a company focused on the discovery and development of drugs to treat a variety of topical diseases, today announced positive results of its ARYS-0502 study of topical ARYS-01 Cream for the treatment of patients with primary Herpes Zoster (Shingles) episodes. "We are greatly excited about these results,” Dr. Norifumi Nakamura, CEO of Janus, announced. “Despite the fact that this was an under-powered study for efficacy, and the first time an agent with this mechanism of action has been evaluated in this population of patients, these data do show remarkably consistent improvements in all the clinical and surrogate markers in all efficacy parameters that suggests topical ARYS-01 Cream can alter the pathophysiology of Herpes Zoster."